SynthesisFrontiers in oncology2024

Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis.

Han Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.